[
  {
    "ts": null,
    "headline": "2 Healthcare Dividend Stocks to Buy and Hold",
    "summary": "These drugmakers have competitive yields and have increased their dividends at a good clip.",
    "url": "https://finnhub.io/api/news?id=cce71d36cf5df4a7be8688d4e0c8c49f74ece8b361ce1db1518c1f7c54cf4a67",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757852100,
      "headline": "2 Healthcare Dividend Stocks to Buy and Hold",
      "id": 136741693,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "These drugmakers have competitive yields and have increased their dividends at a good clip.",
      "url": "https://finnhub.io/api/news?id=cce71d36cf5df4a7be8688d4e0c8c49f74ece8b361ce1db1518c1f7c54cf4a67"
    }
  },
  {
    "ts": null,
    "headline": "Leerink Partners Remains Bullish on Merck & Co. (MRK)",
    "summary": "Merck & Co., Inc. (NYSE:MRK) is one of the best cheap stocks to buy for beginners. On September 10, Leerink Partners analyst Daina Graybosch maintained a bullish stance on Merck & Co., Inc. (NYSE:MRK), giving the stock a Buy rating. The analyst gave the optimistic rating due to Merck & Co., Inc.’s (NYSE:MRK) strategic position […]",
    "url": "https://finnhub.io/api/news?id=3eb51066308d4075582e0b709340d52b509782c1b5db66c43ddc5b73a6fe264d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757830624,
      "headline": "Leerink Partners Remains Bullish on Merck & Co. (MRK)",
      "id": 136741694,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck & Co., Inc. (NYSE:MRK) is one of the best cheap stocks to buy for beginners. On September 10, Leerink Partners analyst Daina Graybosch maintained a bullish stance on Merck & Co., Inc. (NYSE:MRK), giving the stock a Buy rating. The analyst gave the optimistic rating due to Merck & Co., Inc.’s (NYSE:MRK) strategic position […]",
      "url": "https://finnhub.io/api/news?id=3eb51066308d4075582e0b709340d52b509782c1b5db66c43ddc5b73a6fe264d"
    }
  }
]